A Multicentre, Open-label, Randomised, Controlled Study of Target Therapy Based on Tumor Molecular Profiling With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 102
- 试验地点
- 2
- 主要终点
- 3-year DFS
研究概览
简要总结
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with GEMOX in recectable gallbladder carcinoma patients monitored by ctDNA.
详细描述
Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. immuno-histochemistry tests reveal the abnormal activation status of signal pathways involved in study. These information will be used to recommend target therapy which may be more likely to result in a beneficial response. Patients will receive target antitumor agents according to the result of genomic and proteomic profiling and be monitored by circulating tumor DNA(ctDNA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Stable vital signs, ECOG:0-1;
- •Patients have a diagnosis of resectable gallbladder carcinoma by histopathology or cytopathology after radical surgery.
- •Adequate fresh tumor tissue for genome sequencing and immunohistochemistry test; harboring mutations or abnormal activation of erb-b2 receptor tyrosine kinase signal pathway components
- •Life expectancy of more than 18 weeks;
- •T stage≥ T2 or histopathological lymph node positive according to AJCC (8th edition) staging.
- •Adequate hepatic, hematologic and renal functions(ALT≤5×upper limit of normal (ULN), AST≤5×ULN, the Child-Pugh classification for class A or B, white blood cells≥3×10^9/L, neutrophils≥1.5×10^9/L, platelets≥75×10^9/L , hemoglobin ≥ 90g/L, creatinine clearance rate≥60ml/min;
- •Volunteer for this study, have written informed consent and have good Patient compliance;
- •Female patients of childbearing potential and their mates agree to avoid pregnancy.
排除标准
- •Have received following treatment before this study: a. Anti-tumor molecular target therapy; anti-tumor chemotherapy in 6 months; b. lesions have been treated by irradiation; c. participate in other therapeutic or interventional clinical trials.
- •History of other malignancies except carcinoma in-situ of uterine cervix, cured basal cell carcinoma of skin and other malignancies for more than 5 years;
- •Have serious concurrent illness including, but not limited to uncontrolled congestive heart failure(NYHA classification grade III or IV), unstable angina pectoris, unstable cardiac arrhythmias, uncontrolled moderate or serious hypertension(systolic blood pressure >21.3 Kpa or diastolic blood pressure >13.3 Kpa);
- •Have ongoing or active serious infection;
- •Have uncontrolled diabetes mellitus;
- •Psychiatric illness which potentially hamper the ability to willingly give written informed consent and compliance with the study protocol;
- •Active autoimmune diseases require long-term use of steroids or received allotransplantation
- •Other serious illness considered not suitable for this study by investigators.
研究组 & 干预措施
Afatinib with GEMOX
Patients will receive targeted therapy(Afatinib 40mg orally from day 1 to day 21 combined with GEMOX chemotherapy(gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion)
干预措施: gemcitabine and oxaliplatin. (Drug)
Afatinib with GEMOX
Patients will receive targeted therapy(Afatinib 40mg orally from day 1 to day 21 combined with GEMOX chemotherapy(gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion)
干预措施: Afatinib (Drug)
GEMOX
Patients will receive conventional GEMOX chemotherapy (gemcitabine 1000 mg/m2 on days 1 and 8 of each cycle by IV infusion and oxaliplatin 100 mg/m2 on day 1 of each cycle by IV infusion）
干预措施: gemcitabine and oxaliplatin. (Drug)
结局指标
主要结局
3-year DFS
时间窗: up to 3 years
3-year disease free survival rates:The progression is defined consistent with contrast enhanced MRI/CT.
次要结局
- 3-year OS(up to 3 years)
研究者
Yingbin Liu, MD, PhD, FACS
Prof.
Shanghai Jiao Tong University School of Medicine